LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS

N/A

Manufactured by Cipla USA Inc.

14,515 FDA adverse event reports analyzed

Last updated: 2026-04-14

About LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS

LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Cipla USA Inc.. The most commonly reported adverse reactions for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS include NAUSEA, FATIGUE, DIARRHOEA, DRUG INEFFECTIVE, DIZZINESS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS.

Top Adverse Reactions

NAUSEA534 reports
FATIGUE523 reports
DIARRHOEA470 reports
DRUG INEFFECTIVE463 reports
DIZZINESS384 reports
PAIN381 reports
HEADACHE328 reports
DYSPNOEA319 reports
COUGH282 reports
VOMITING274 reports
ASTHENIA273 reports
ARTHRALGIA263 reports
ANGIOEDEMA261 reports
PRURITUS241 reports
FALL236 reports
MALAISE235 reports
PAIN IN EXTREMITY221 reports
INSOMNIA218 reports
HYPERTENSION209 reports
WEIGHT DECREASED198 reports
RASH189 reports
FEELING ABNORMAL185 reports
ANXIETY180 reports
CONSTIPATION176 reports
BLOOD PRESSURE INCREASED171 reports
FLUSHING171 reports
OFF LABEL USE171 reports
BACK PAIN170 reports
HYPOTENSION160 reports
DEHYDRATION157 reports
MUSCLE SPASMS157 reports
PARAESTHESIA146 reports
DEATH137 reports
WEIGHT INCREASED134 reports
DECREASED APPETITE131 reports
PNEUMONIA131 reports
DEPRESSION130 reports
ABDOMINAL DISCOMFORT127 reports
GAIT DISTURBANCE126 reports
SOMNOLENCE126 reports
PYREXIA120 reports
PRODUCT DOSE OMISSION ISSUE119 reports
ACUTE KIDNEY INJURY117 reports
BLOOD GLUCOSE INCREASED117 reports
URINARY TRACT INFECTION115 reports
ABDOMINAL PAIN113 reports
HYPOAESTHESIA113 reports
RENAL FAILURE108 reports
ABDOMINAL PAIN UPPER107 reports
DRUG DOSE OMISSION107 reports
CONDITION AGGRAVATED105 reports
HOT FLUSH105 reports
VISION BLURRED105 reports
RENAL FAILURE ACUTE103 reports
PERIPHERAL SWELLING101 reports
TREMOR101 reports
MYALGIA100 reports
CONFUSIONAL STATE98 reports
INJECTION SITE PAIN98 reports
ANAEMIA97 reports
CHEST PAIN95 reports
ERYTHEMA94 reports
HYPERHIDROSIS94 reports
SYNCOPE93 reports
DRUG INTERACTION88 reports
PSORIASIS87 reports
ALOPECIA86 reports
COVID 1986 reports
MUSCULAR WEAKNESS86 reports
OEDEMA PERIPHERAL85 reports
CEREBROVASCULAR ACCIDENT84 reports
LOSS OF CONSCIOUSNESS81 reports
HYPONATRAEMIA80 reports
MEMORY IMPAIRMENT80 reports
FEELING HOT79 reports
NASOPHARYNGITIS78 reports
DRUG HYPERSENSITIVITY76 reports
MYOCARDIAL INFARCTION76 reports
URTICARIA75 reports
CHRONIC KIDNEY DISEASE73 reports
NEUROPATHY PERIPHERAL73 reports
BALANCE DISORDER70 reports
PRODUCT QUALITY ISSUE70 reports
DYSPEPSIA69 reports
CHILLS68 reports
SWOLLEN TONGUE68 reports
DIABETES MELLITUS67 reports
DYSPHAGIA67 reports
HYPERSENSITIVITY66 reports
CHEST DISCOMFORT65 reports
GASTROOESOPHAGEAL REFLUX DISEASE65 reports
INCORRECT DOSE ADMINISTERED63 reports
COMPLETED SUICIDE62 reports
HEART RATE INCREASED62 reports
JOINT SWELLING62 reports
PALPITATIONS62 reports
VISUAL IMPAIRMENT62 reports
CARDIAC ARREST61 reports
BURNING SENSATION60 reports
CONTUSION60 reports

Report Outcomes

Out of 7,625 classified reports for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS:

Serious 56.0%Non-Serious 44.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female4,047 (56.3%)
Male3,139 (43.7%)
Unknown3 (0.0%)

Reports by Age

Age 64171 reports
Age 61149 reports
Age 67147 reports
Age 60145 reports
Age 65145 reports
Age 62139 reports
Age 63138 reports
Age 58132 reports
Age 68132 reports
Age 69132 reports
Age 59131 reports
Age 54130 reports
Age 56126 reports
Age 57124 reports
Age 70116 reports
Age 66114 reports
Age 53112 reports
Age 71107 reports
Age 52106 reports
Age 73106 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS?

This profile reflects 14,515 FDA FAERS reports that mention LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS?

Frequently reported terms in FAERS include NAUSEA, FATIGUE, DIARRHOEA, DRUG INEFFECTIVE, DIZZINESS, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS?

Labeling and FAERS entries often list Cipla USA Inc. in connection with LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.